These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35932588)

  • 1. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
    Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
    Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
    Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
    Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
    Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
    World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.
    Lohkamp LN; Schinz M; Gehlhaar C; Guse K; Thomale UW; Vajkoczy P; Heppner FL; Koch A
    PLoS One; 2016; 11(6):e0156422. PubMed ID: 27253461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
    Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
    Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
    Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
    PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study].
    Zheng LM; Gong J; Zou Y; Zhang MN; Yu TP; Hou J; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):229-235. PubMed ID: 33677887
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
    Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
    J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
    Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
    Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
    Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
    Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant transformation of pleomorphic xanthoastrocytoma and differential diagnosis: case report.
    Watanabe N; Ishikawa E; Kohzuki H; Sakamoto N; Zaboronok A; Matsuda M; Shibuya M; Matsumura A
    BMC Neurol; 2020 Jan; 20(1):21. PubMed ID: 31941461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells.
    Barresi V; Simbolo M; Ciaparrone C; Pedron S; Mafficini A; Scarpa A
    Histopathology; 2022 Nov; 81(5):661-669. PubMed ID: 35945679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation.
    Kim SH; Hwang K; Lee KS; Choe G; Kim CY
    World Neurosurg; 2020 Jul; 139():577-581. PubMed ID: 32348888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults.
    Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK
    Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of a Promoter Mutation in TERT in Malignant Transformation of Pleomorphic Xanthoastrocytoma.
    Hosono J; Nitta M; Masui K; Maruyama T; Komori T; Yokoo H; Saito T; Muragaki Y; Kawamata T
    World Neurosurg; 2019 Jun; 126():624-630. PubMed ID: 30599247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
    Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
    J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
    Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
    Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.